Radioimmunotherapy with Yttrium-90 Ibritumomab tiuxetan for patients with relapsed cd20+ B-Cell non-Hodgkin’s Lymphoma

Medicine & Life Sciences

• ibritumomab tiuxetan 100%
• Radioimmunotherapy 84%
• B-Cell Lymphoma 62%
• Non-Hodgkin's Lymphoma 57%
• Rituximab 40%
• Antibodies 12%
• Anti-Idiotypic Antibodies 11%
• Radiation 10%
• Radioisotopes 9%
• Platelet Count 9%
• Yttrium-90 6%
• Monoclonal Antibodies 6%
• Drug Approval 6%
• Chelating Agents 5%
• Cold Temperature 4%
• Therapeutics 3%
• Stem Cells 3%
• Food 3%
• Health Care Outcome Assessment 3%
• Clinical Trials 3%
• Drug Therapy 2%
• Pharmaceutical Preparations 1%